Stock ABVX ABIVAX
Add to a list
To use this feature you must be a member
Log inSign up

Abivax Stock

Equities

ABVX

FR0012333284

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:35:08 2025-02-06 am EST 		After market 03:20:48 pm
5.820 EUR +2.46% Intraday chart for Abivax 5.905 +1.46%
Jan. 10 Abivax: over 1,000 patients enrolled in the ABTECT study CF
Jan. 09 Abivax Reaches 82% Enrollment in Phase 3 Ulcerative Colitis Trial MT

Valuation: Abivax

Capitalization 360M 375M 338M 299M 536M 32.74B 596M 4.08B 1.51B 13.46B 1.41B 1.38B 57.07B P/E ratio 2024 *
-2.03x
P/E ratio 2025 * -1.9x
Enterprise value 328M 341M 308M 273M 488M 29.82B 543M 3.72B 1.38B 12.26B 1.28B 1.25B 51.97B EV / Sales 2024 *
40.8x
EV / Sales 2025 * 44.7x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Abivax

Dynamic Chart

Latest news: Abivax

Abivax: over 1,000 patients enrolled in the ABTECT study Jan. 10 CF
Abivax Reaches 82% Enrollment in Phase 3 Ulcerative Colitis Trial Jan. 09 MT
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Jan. 09 CI
Abivax: resignation of former Chairman of the Board Dec. 24 CF
Abivax SA Announces Resignation of Philippe Pouletty as Director, Effective December 31, 2024 Dec. 23 CI
JMP Securities Initiates Abivax at Market Outperform With $33 Price Target Dec. 04 MT
Abivax: appointment of board observer Nov. 14 CF
Abivax SA Announces Board Observer & Advisor Appointments Nov. 13 CI
Abivax: recruitment begins for Crohn's trial 24-10-04 CF
Abivax Enrolls First Patient in Phase 2b Trial of Obefazimod to Treat Crohn's Disease 24-10-03 MT
Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease 24-10-03 CI
Sector Update: Health Care Stocks Steady Premarket Thursday 24-10-03 MT
Abivax: positive results after two years of maintenance 24-10-03 CF
More news

Last Transcript: Abivax

Logo Abivax
ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024
24-04-08
More transcripts

Analysts' recommendations: Abivax

JMP Securities Initiates Abivax at Market Outperform With $33 Price Target Dec. 04 MT
BTIG Initiates Abivax at Buy Rating With $43 Price Target 24-05-20 MT
Abivax: share price rises as two analysts express optimism 24-04-29 CF
Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target 24-04-29 MT
Guggenheim Starts Abivax With Buy Rating, $50 Price Target 24-04-29 MT
More recommendations

Press Releases: Abivax

Abivax Publishes 2025 Financial Calendar Jan. 28 EQ
Abivax Publishes 2025 Financial Calendar Jan. 28 AQ
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress Jan. 24 AQ
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress Jan. 23 EQ
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Jan. 09 EQ
More press releases

News in other languages: Abivax

Abivax : Document AMF CP. 2025DD1018475 Feb. 04
Abivax : Document AMF CP. 2025DD1018279 Feb. 03
Abivax : Document AMF CP. 2025DD1018162 Feb. 03
Abivax : Document AMF CP. 2025DD1018160 Feb. 03
Le marché met le feu à ses idoles Jan. 28
More news

Quotes and Performance

1 day+2.29%
1 week-1.02%
Current month-3.81%
1 month-17.00%
3 months-39.29%
6 months-44.35%
Current year-14.05%
More quotes

Course Extremes

1 week
5.62
Extreme 5.62
6.07
1 month
5.62
Extreme 5.62
7.15
Current year
5.62
Extreme 5.62
7.30
1 year
5.62
Extreme 5.62
15.42
3 years
5.60
Extreme 5.6
26.25
5 years
5.60
Extreme 5.6
39.00
10 years
3.87
Extreme 3.87
39.00
More quotes

Managers and Directors: Abivax

Director TitleAgeSince
Marc M. P. de Garidel CEO
 Chief Executive Officer 66 2023-05-04
Didier Blondel DFI
 Director of Finance/CFO - 2017-01-01
Fabio Cataldi CTO
 Chief Tech/Sci/R&D Officer 58 2024-07-14
Manager TitleAgeSince
Corinna Zur Bonsen-Thomas CHM
 Chairman - 2022-08-15
Kinam Hong BRD
 Director/Board Member - -
June Lee BRD
 Director/Board Member 59 2023-07-10
More insiders

Other Biotechnology & Medical Research

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
ABIVAX Stock Abivax
+2.29%-1.02%-49.04%-75.06%375M
LONZA GROUP AG Stock Lonza Group AG
-0.36%+3.32%+36.46%-1.96%49.15B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.70%+3.72%-2.50%-17.79%37.29B
CELLTRION, INC. Stock Celltrion, Inc.
+0.51%-1.05%+3.49%+22.84%26.22B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.62%-0.86%-26.10%-26.45%16.22B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+0.21%-4.98%+66.47%+75.69%15.81B
MODERNA, INC. Stock Moderna, Inc.
+2.37%-14.10%-63.37%-78.54%13.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+3.72%+4.76%+12.70%-26.60%11.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+2.35%+3.54%+20.27%+106.78%11.01B
TEMPUS AI, INC. Stock Tempus AI, Inc.
+11.85%+36.26% - - 10.89B
Average +1.91%+3.02%-0.18%-2.34% 19.24B
Weighted average by Cap. +1.75%+3.18%+10.59%+2.09%
See all sector performances

Financials

2024 *2025 *
Net sales 8.04M 8.37M 7.54M 6.69M 11.96M 731M 13.31M 91.14M 33.75M 301M 31.39M 30.76M 1.27B 5.76M 6M 5.41M 4.8M 8.58M 524M 9.54M 65.36M 24.2M 216M 22.51M 22.06M 914M
Net income -171M -178M -160M -142M -254M -15.54B -283M -1.94B -717M -6.39B -667M -654M -27.09B -197M -205M -185M -164M -293M -17.92B -326M -2.23B -827M -7.36B -769M -754M -31.23B
Net Debt -32.15M -33.49M -30.17M -26.75M -47.86M -2.93B -53.23M -365M -135M -1.2B -126M -123M -5.1B -102M -107M -96.05M -85.17M -152M -9.31B -169M -1.16B -430M -3.83B -400M -392M -16.23B
More financial data * Estimated data

Company Profile

Logo Abivax
Abivax develops innovative treatments modulating the body's natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Employees
62
Sector
Biotechnology & Medical Research
Calendar
2025-03-23 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
25-02-06 5.820 € +2.46% 11,373
25-02-05 5.680 € -2.91% 22,581
25-02-04 5.850 € +0.17% 12,994
25-02-03 5.840 € -3.31% 38,202
25-01-31 6.040 € +2.90% 39,091

Real-time Euronext Paris, February 06, 2025 at 07:13 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart ABIVAX More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
BBB
surperformance-ratings-light-chart ABIVAXMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.680EUR
Average target price
29.34EUR
Spread / Average Target
+416.55%
Consensus
Profit revisions
estimates-change-chart ABIVAX Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ABIVAX Company calendar
  1. Stock Market
  2. Equities
  3. ABVX Stock